| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [2] |
国家肿瘤质控中心乳腺癌专家委员会, 中国抗癌协会乳腺癌专业委员会, 中国抗癌协会肿瘤药物临床研究专业委员会. 中国晚期乳腺癌规范诊疗指南(2020版)[J]. 中华肿瘤杂志, 2020, 42(10): 781-797.
|
| [3] |
Smit DJ, Pantel K, Jücker M. Circulating tumor cells as a promising target for individualized drug susceptibility tests in cancer therapy[J]. Biochem Pharmac, 2021, 188: 114589.
|
| [4] |
Chelakkot C, Yang H, Shin YK. Relevance of circulating tumor cells as predictive markers for cancer incidence and relapse[J]. Pharmaceuticals, 2022, 15(1): 75.
|
| [5] |
Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases[J]. Clin Cancer Rese, 2004, 10(20): 6897-6904.
|
| [6] |
Spizzo G, Fong D, Wurm M, et al. EpCAM expression in primary tumour tissues and metastases: An immunohistochemical analysis[J]. J Clin Pathol, 2011, 64(5): 415-420.
|
| [7] |
Debnath P, Huirem RS, Dutta P, et al. Epithelial–mesenchymal transition and its transcription factors[J]. Biosci Rep, 2022, 42(1): BSR20211754.
|
| [8] |
Buyuk B, Jin S, Ye K. Epithelial-to-mesenchymal transition signaling pathways responsible for breast cancer metastasis[J]. Cell Mol Bioengineer, 2021, 15(1): 1-13.
|
| [9] |
Topa J, Grešner P, Żaczek A J, et al. Breast cancer circulating tumor cells with mesenchymal features—an unreachable target?[J]. Cell Mol Life Sci, 2022, 79(2): 81.
|
| [10] |
Mendelaar PAJ, Kraan J, Van M, et al. Defining the dimensions of circulating tumor cells in a large series of breast, prostate, colon, and bladder cancer patients[J]. Mol Oncol, 2021, 15(1): 116-125.
|
| [11] |
Rahmati M, Chen X. Separation of circulating tumor cells from blood using dielectrophoretic DLD manipulation[J]. Biomed Microdevices, 2021, 23(4): 49.
|
| [12] |
Farasat M, Chavoshi SM, Bakhshi A, et al. A dielectrophoresis-based microfluidic chip for trapping circulating tumor cells using a porous membrane[J]. J Micromechan Microengineer, 2021, 32(1): 015008.
|
| [13] |
Kalyan S, Torabi C, Khoo H, et al. Inertial microfluidics enabling clinical research[J]. Micromachines, 2021, 12(3): 257.
|
| [14] |
Soler A, Cayrefourcq L, Mazel M, et al. EpCAM-independent enrichment and detection of viable circulating tumor cells using the EPISPOT assay[M]//Circulating Tumor Cells. Humana Press, New York, NY, 2017: 263-276.
|
| [15] |
Park HS, Han HJ, Lee S, et al. Detection of circulating tumor cells in breast cancer patients using cytokeratin-19 real-time RT-PCR[J]. Yonsei Med J, 2017, 58(1): 19-26.
|
| [16] |
Descamps L, Le Roy D, Deman AL. Microfluidic-based technologies for CTC isolation: A review of 10 years of intense efforts towards liquid biopsy[J]. Int J Mol Sci, 2022, 23(4): 1981.
|
| [17] |
Farshchi F, Hasanzadeh M. Microfluidic biosensing of circulating tumor cells (CTCs): recent progress and challenges in efficient diagnosis of cancer[J]. Biomed Pharmacother, 2021, 134: 111153.
|
| [18] |
Marmot MG, Altman DG, Cameron DA, et al. The benefits and harms of breast cancer screening: An independent review[J]. Br J Cancer, 2013, 108(11): 2205-2240.
|
| [19] |
Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk[J]. JAMA, 2012, 307(13): 1394-1404.
|
| [20] |
Gao Y, Fan WH, Duan C, et al. Enhancing the screening efficiency of breast cancer by combining conventional medical imaging examinations with circulating tumor cells[J]. Front Oncol 2021, 11: 643003.
|
| [21] |
Janni WJ, Rack B, Terstappen LW, et al. Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancerJ]. Clin Cancer Res, 2016, 22(10): 2583-2593.
|
| [22] |
Bidard FC, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data[J]. Lancet Oncol, 2014, 15(4): 406-414.
|
| [23] |
龚嘉, 徐峰, 周美容, 等.循环肿瘤细胞与早期乳腺癌临床病理特征的相关性[J]. 中南大学学报(医学版), 2019, 44(9): 1016-1022.
|
| [24] |
Zhou M, Jiang L, Fan Y, et al. Correlation between circulating tumor cells and different molecular biological characteristics in breast cancer patients[J]. Gland Surg, 2022, 11(2): 466-471.
|
| [25] |
李蕾, 刘毅, 张少华, 等. 循环肿瘤细胞检测在不同阶段不同类型乳腺癌中的应用及意义[J]. 中华医学杂志, 2014, 100(36): 2812-2815.
|
| [26] |
Sanches SM, Braun AC, Calsavara VF, et al. Comparison of hormonal receptor expression and HER2 status between circulating tumor cells and breast cancer metastases[J]. Clinics, 2021, 76: e2971.
|
| [27] |
Fehm T, Hoffmann O, Aktas B, et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells[J]. Breast Cancer Res, 2009, 11(4): 1-9.
|
| [28] |
Bouris P, Skandalis SS, Piperigkou Z, et al. Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells[J]. Matrix Biol, 2015, 43: 42-60.
|
| [29] |
Müller V, Banys-Paluchowski M, Friedl TWP, et al. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program[J]. ESMO Open, 2021, 6(6): 100299.
|
| [30] |
Georgoulias V, Bozionelou V, Agelaki S, et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19 mRNA-positive circulating tumor cells: results of a randomized phase Ⅱ study[J]. Ann Oncol, 2012, 23(7): 1744-1750.
|
| [31] |
Schramm A, Friedl TWP, Schochter F, et al. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program[J]. Arch Gynecol Obstet, 2016, 293(2): 271-281.
|
| [32] |
Shliakhtunou YA. CTCs-oriented adjuvant personalized cytostatic therapy non-metastatic breast cancer patients: continuous non-randomized prospective study and prospective randomized controlled study[J]. Breast Cancer Res Treat, 2021, 186(2): 439-451.
|
| [33] |
Yan WT, Cui X, Chen Q, et al. Circulating tumor cell status monitors the treatment responses in breast cancer patients: A meta-analysis[J]. Sci Rep, 2017, 7(1): 1-12.
|
| [34] |
Duma MN. Association of circulating tumor cell status with benefit of radiotherapy and survival in early-stage breast cancer[J]. Strahlenther Onkol, 2018, 194(11): 1069-1071.
|
| [35] |
Wang J, Wang X, Chen R, et al. Circulating tumor cells may serve as a supplement to RECIST in neoadjuvant chemotherapy of patients with locally advanced breast cancer[J]. Int J Clin Oncol, 2022, 27(5): 889-898.
|